P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL
HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 12-12
10.1097/01.hs9.0000829588.31575.a9